Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Oxyntomodulin Analog
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Preclinical
Sponsor : EnteraBio Ltd
Deal Size : Undisclosed
Deal Type : Collaboration
OPKO Health, Entera Bio Partner on Oral Dual Agonist GLP-1
Details : The collaborations aims to advance the oral dual agonist GLP-1/glucagon peptide OPK-88006 (oxyntomodulin analog) as a once-daily tablet treatment for patients with obesity.
Product Name : OPK-88006
Product Type : Peptide
Upfront Cash : Undisclosed
March 19, 2025
Lead Product(s) : Oxyntomodulin Analog
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Preclinical
Sponsor : EnteraBio Ltd
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : V350A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
OPKO Health’s ModeX Announces Epstein-Barr Virus Vaccine in Phase I Study
Details : V350A is a vaccine candidate based on MDX2201 ferritin nanoparticle vaccine platform, being investigated for the treatment of epstein-barr virus infection.
Product Name : V350A
Product Type : Vaccine
Upfront Cash : Inapplicable
January 07, 2025
Lead Product(s) : V350A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Somatrogon
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : HealthCare Royalty
Deal Size : $250.0 million
Deal Type : Agreement
OPKO and HealthCare Royalty Enter $250M Note Purchase Agreement Secured by NGENLA Payments
Details : OPKO retained a significant portion of Ngenla (somatrogon) through the agreement. It is an approved product, which is indicated for pediatric patients with growth hormone deficiency.
Product Name : Ngenla
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
July 17, 2024
Lead Product(s) : Somatrogon
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : HealthCare Royalty
Deal Size : $250.0 million
Deal Type : Agreement
Lead Product(s) : MDX2202
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : BARDA
Deal Size : $110.0 million
Deal Type : Funding
ModeX Secures $35M For COVID Antibodies, $16M For Influenza Program
Details : The funding will support the development of a novel multispecific antibody to SARS-CoV-2 from preclinical and influenza multispecifics with gene and/or protein delivery modalities.
Product Name : MDX2202
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
July 10, 2024
Lead Product(s) : MDX2202
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : BARDA
Deal Size : $110.0 million
Deal Type : Funding
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Discovery
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Agreement
Details : The agreement aims to advance a platform and specific candidates addressing a range of viral infectious diseases and will enable research, development and clinical evaluation of potent multispecific antibodies, based on ModeX proprietary MSTAR technology...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
September 28, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Discovery
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : MDX-2201
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : ModeX and Merck will jointly advance MDX-2201 to an IND application filing, after which Merck will be responsible for clinical and regulatory activities and product commercialization. MDX-2201 leverages ModeX’s innovative biologics platform to target m...
Product Name : MDX-2201
Product Type : Vaccine
Upfront Cash : Undisclosed
August 03, 2023
Lead Product(s) : MDX-2201
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Sponsor : OPKO Health
Deal Size : $300.0 million
Deal Type : Acquisition
Details : ModeX Therapeutics has developed highly flexible multi-specific antibody technology platforms with broad targeting and functional capabilities, simpler manufacturing and potentially better specificity and safety, providing significant differentiation fro...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
September 05, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Sponsor : OPKO Health
Deal Size : $300.0 million
Deal Type : Acquisition
Lead Product(s) : Calcifediol
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : VFMCRP
Deal Size : Inapplicable
Deal Type : Inapplicable
RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP
Details : RAYALDEE extended-release capsules are indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
Product Name : Rayaldee
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
March 02, 2022
Lead Product(s) : Calcifediol
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : VFMCRP
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : OPK88001
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : CAMP4 Therapeutics
Deal Size : $93.5 million
Deal Type : Licensing Agreement
OPKO Health Licenses Oligonucleotide Therapeutics Platform to CAMP4 Therapeutics
Details : CAMP4 is pioneering a novel approach to programmable therapeutics that combines a deep understanding of regulatory RNA and gene expression with a complementary and customizable oligonucleotide modality.
Product Name : OPK88001
Product Type : Undisclosed
Upfront Cash : Undisclosed
December 07, 2021
Lead Product(s) : OPK88001
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : CAMP4 Therapeutics
Deal Size : $93.5 million
Deal Type : Licensing Agreement
Lead Product(s) : Somatrogon
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Somatrogon is an investigational biologic product that is glycosylated and comprises amino acid sequence of human growth hormone and one copy of C-terminal peptide from beta chain used for treatment of growth hormone deficiency (GHD) in pediatric patient...
Product Name : Ngenla
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
September 24, 2021
Lead Product(s) : Somatrogon
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable